KEY TAKEAWAY POINTS

• The evolution of surgical glaucoma treatment has led to the development of procedures attempting
to achieve better efficacy, but having variable complication profiles

• MIGS devices have the capacity to provide efficacy and reduce complications with rapid
patient recovery

• The HYDRUS Microstent has a Tri-Modal ® mechanism of action that bypasses the trabecular
meshwork, scaffolds Schlemm’s canal, and spans approximately 90° ensuring access to collector
channels in the nasal region

• The pivotal clinical data demonstrate that combining the HYDRUS Microstent with cataract surgery
provides a durable decrease in IOP in adults with mild to moderate primary open-angle glaucoma
with a concurrent decrease in medication dependence